CA-GLOBALLOGIC
13.10.2021 14:03:13 CEST | Business Wire | Press release
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Inspira Technologies to develop an algorithm-enhanced digital platform powering the ART device — an Early Extracorporeal Respiratory Support system targeting respiratory failure patients such as those diagnosed with COVID-19. The project underscores GlobalLogic’s deep expertise in Class II and Class III software creation for medical devices that must meet strict regulatory requirements.
Inspira Technologies created the ART, a novel low-flow early extracorporeal approach to address the significant patient population whose condition continues to deteriorate following noninvasive ventilation. As of today, the only treatment available for them after noninvasive ventilation is the highly invasive mechanical ventilation. The ART device utilizes a hemo-protective flow approach designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously, potentially minimizing the need for mechanical ventilation. The ART is designed to enrich ~200cc of blood at any given point, elevating the oxygen saturation levels in one minute.
GlobalLogic will support Inspira in the development of the ART control platform’s algorithms responsible for monitoring and managing the early rebalancing of the patient’s oxygen saturation levels. These algorithms will also activate and control proprietary technologies and data collected from advanced sensors that measure oxygen saturation, blood temperature, hemoglobin, and hematocrit levels as well as blood pressure and flow. Inspira Technologies notes that the ART could potentially minimize the need for mechanical ventilators for hypoxemic patients, such as COVID patients. Additionally, GlobalLogic will be leading the verification testing of these systems.
“Software plays an increasingly more crucial role in driving the overall efficacy of medical devices today. It also enhances the patient engagement with and medical staff’s use of such technologies,” said Shashank Samant, President & CEO, GlobalLogic. “For nearly twenty years, we’ve worked with world-renowned medical device manufacturers as well as start-ups in today’s MedTech innovation hotspots. We’re honored to have the opportunity to play such a pivotal role in bringing to market another disruptive technology, the ART. Particularly at such a critical time when there is a dire need for advanced treatment options.”
GlobalLogic possesses deep competencies centered around key medical device capabilities: device performance; data collection and analysis; and intuitive medical personnel and patient experiences. Specific to the ART, GlobalLogic’s engineering contributions will help Inspira Technologies produce a digitally enhanced artificial lung while empowering medical staff with vital patient stats needed to easily monitor progress and effectiveness.
“It was imperative that we find a partner with both specialized MedTech capabilities and the scale needed to meet our design objectives as we are committed to bring to market a much-needed technology — filling a critical gap in today’s medical treatment options for respiratory failure patients who continue to deteriorate after treatment with noninvasive ventilation devices. Our decision to partner with GlobalLogic was driven by its proven ability in the medical device landscape and the capacity to meet aggressive time-to-market requirements with reliable solutions,” explained Dagi Ben-Noon, CEO, Inspira Technologies.
ART is currently in development with anticipated regulatory submission of its ART ECLS at the end of 2022.
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise — we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the healthcare and life sciences, communications, financial services, automotive, technology, media and entertainment, manufacturing, and semiconductor industries. GlobalLogic is a Hitachi Group Company.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective early extracorporeal respiratory support system with an intent to function as an “Artificial Lung” for deteriorating respiratory patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient’s need for mechanical ventilation. The Company’s product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA). For more information, please visit our corporate website: https://inspira-technologies.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005237/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 11:12:00 CEST | Press release
New assessment and risk assurance framework helps enterprises gain unified visibility, prioritise remediation and scale AI securely LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 10:00:00 CEST | Press release
Globally, people are united in their top personal worries: Financial and health issues rank at the top in 2026, averaging 13 percentage points ahead of other concerns.Financial pressure is prominent across Europe, rising in France, Germany, and U.K., and emerging as a top concern in newly measured markets, Spain and Switzerland.Allianz published these results in “The Allianz 3am Report 2026,” which surveyed 10,000 people across 10 countries worldwide about what keeps them awake at night.Addressing financial concerns requires accessible, targeted financial and risk education. To support this, Allianz has launched the “Allianz School For Life” learning platform. Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countri
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 08:40:00 CEST | Press release
A long-established Japanese general contractor will contribute construction expertise to advance Fusion Pilot Plant development toward commercially viable fusion power. Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 07:15:00 CEST | Press release
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exitThe proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor typesMyricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patientsThe transaction valued at up to $1.5 billion including $1.1 billion cash upfront Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discove
Global New Material International Wins Technology Innovation Best Practice Award at Sino-European ESG Conference6.7.2026 05:59:00 CEST | Press release
Global New Material International Holdings Ltd. has received the Technology Innovation Best Practice Award at the Third Sino-European Corporate ESG Best Practice Conference recently in Mainz, Germany, in recognition of its efforts to advance sustainable development through material innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260705533555/en/ Thorsten Giehler (L), Director of the Economic, Social Development and Employment Division of The German Society for International Cooperation (GIZ), delivered the award to Zhou Fangchao, Executive Director and Vice President of Global New Material International. The annual conference, initiated by the Chinese Consulate General in Frankfurt and jointly organized with Chinese and European partners, recognizes corporate best practices in environmental, social and governance (ESG) performance. This year's event brought together government officials, business leaders and exper
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom